Oncolytics Biotech (ONCY) said Wednesday that Germany's Paul-Ehrlich-Institute has approved the continuation of patient enrollment in Cohort 5 of its GOBLET study.

The company said the cohort will assess pelareorep combined with modified FOLFIRINOX with or without atezolizumab in patients newly diagnosed with pancreatic ductal adenocarcinoma.

The approval, which paves the way for complete enrollment of 30 patients in Stage 1, follows a positive safety review by the Data Safety Monitoring Board that recommended the study's progression, Oncolytics Biotech said.

The company also said it will present early safety data later in January, with preliminary efficacy results anticipated in H2.

Oncolytics Biotech's shares were up nearly 7% in recent Wednesday premarket activity.